UNSPSC 51162738: Sobrerol

This classification denotes an expectorant with the molecular formula C10H18O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AI0NX02O35, chemically known as 5-hydroxy-alpha,alpha,4-trimethylcyclohex-3-ene-1-methanol but more generally known as sobrerol, which bears US NIH Compound Identifier 91463. European Medicines Agency schedules Sobrerol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15264MIG.

World Health Organization schedules sobrerol in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, SOBREROL remains US FDA's Preferred Term for this commodity. SMILES: CC1=CCC(CC1O)C(C)(C)O.

UNSPSC 51162738 Sobrerol is a Commodity code that captures pharmaceutical procurement by state and local government bodies, though recent activity shows the code is being applied to a broader range of pharmaceutical and drug-management products than the abstract code name suggests. State and local buyers under this code are sourcing naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing frameworks. Issuing bodies include county health departments (Seminole County, Florida) and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, administered by the Minnesota Department of Administration). The work involves identifying, pricing, and delivering pharmaceuticals and health-related products to public health facilities and participating state and local government members, with vendors typically required to meet FDA compliance, cGMP certification, chain-of-supply security standards, and insurance coverage thresholds ranging from $2 million to $5 million per occurrence depending on the scope.

Recent activity spans Florida and Minnesota with multistate reach. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with bids due July 26, 2023 and a two-year initial contract term plus one-year renewal option. MMCAP issued RFP S1070000015802 on January 20, 2026, to establish multi-vendor contracts for generic pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, evaluations weighted heavily on price competitiveness (75 percent), and contract effectiveness July 1, 2026. Both procurements require vendors to handle their own shipping and delivery, maintain electronic data interchange capability, and comply with federal and state pharmaceutical supply-chain security requirements. Neither opportunity specifies set-aside designations for disadvantaged enterprises.